Biomea Fusion launches public offering of common stock and warrants

Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage diabetes and obesity company based in San Carlos, Calif., announced the commencement of an underwritten public offering of shares of its common stock and pre-funded warrants to purchase shares of its common stock.

The company stated that certain investors may receive pre-funded warrants in lieu of common stock. Biomea also intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the total shares of common stock and pre-funded warrants offered. All securities in the offering will be sold by Biomea.

Konik Capital Partners, LLC, a division of T.R. Winston & Company, is acting as sole underwriter for the proposed offering.

The offering is being made pursuant to an effective shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission on Aug. 5, 2025, which was declared effective on Aug. 15, 2025.

The company noted that the offering is subject to market and other conditions, and there is no assurance as to whether or when it may be completed, or as to its final size or terms.

You May Also Be Interested In

• Biomea Fusion cancels planned public offering citing market conditions
• Flywire adds ex-GitLab CTO Sabrina Farmer to its board
• Limbach names Adam Prior as VP of investor relations